Global, Regional, and National Economic Consequences of Stroke.
disability-adjusted life years
global health
health economics
stroke
Journal
Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
medline:
31
8
2023
pubmed:
27
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
An understanding of global, regional, and national macroeconomic losses caused by stroke is important for allocation of clinical and research resources. The authors investigated the macroeconomic consequences of stroke disease burden in the year 2019 in 173 countries. Disability-adjusted life year data for overall stroke and its subtypes (ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage) were collected from the GBD study (Global Burden of Disease) 2019 database. Gross domestic product (GDP, adjusted for purchasing power parity [PPP]) data were collected from the World Bank; GDP and disability-adjusted life year data were combined to estimate macroeconomic losses using a value of lost welfare (VLW) approach. All results are presented in 2017 international US dollars adjusted for PPP. Globally, in 2019, VLW due to stroke was $2059.67 billion or 1.66% of the global GDP. Global VLW/GDP for stroke subtypes was 0.78% (VLW=$964.51 billion) for ischemic stroke, 0.71% (VLW=$882.81 billion) for intracerebral hemorrhage, and 0.17% (VLW=$212.36 billion) for subarachnoid hemorrhage. The Central European, Eastern European, and Central Asian GBD super-region reported the highest VLW/GDP for stroke overall (3.01%), ischemic stroke (1.86%), and for subarachnoid hemorrhage (0.26%). The Southeast Asian, East Asian, and Oceanian GBD super-region reported the highest VLW/GDP for intracerebral hemorrhage (1.48%). The global macroeconomic consequences related to stroke are vast even when considering stroke subtypes. The present quantification may be leveraged to help justify increased spending of finite resources on stroke in an effort to improve outcomes for patients with stroke globally.
Sections du résumé
BACKGROUND
An understanding of global, regional, and national macroeconomic losses caused by stroke is important for allocation of clinical and research resources. The authors investigated the macroeconomic consequences of stroke disease burden in the year 2019 in 173 countries.
METHODS
Disability-adjusted life year data for overall stroke and its subtypes (ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage) were collected from the GBD study (Global Burden of Disease) 2019 database. Gross domestic product (GDP, adjusted for purchasing power parity [PPP]) data were collected from the World Bank; GDP and disability-adjusted life year data were combined to estimate macroeconomic losses using a value of lost welfare (VLW) approach. All results are presented in 2017 international US dollars adjusted for PPP.
RESULTS
Globally, in 2019, VLW due to stroke was $2059.67 billion or 1.66% of the global GDP. Global VLW/GDP for stroke subtypes was 0.78% (VLW=$964.51 billion) for ischemic stroke, 0.71% (VLW=$882.81 billion) for intracerebral hemorrhage, and 0.17% (VLW=$212.36 billion) for subarachnoid hemorrhage. The Central European, Eastern European, and Central Asian GBD super-region reported the highest VLW/GDP for stroke overall (3.01%), ischemic stroke (1.86%), and for subarachnoid hemorrhage (0.26%). The Southeast Asian, East Asian, and Oceanian GBD super-region reported the highest VLW/GDP for intracerebral hemorrhage (1.48%).
CONCLUSIONS
The global macroeconomic consequences related to stroke are vast even when considering stroke subtypes. The present quantification may be leveraged to help justify increased spending of finite resources on stroke in an effort to improve outcomes for patients with stroke globally.
Identifiants
pubmed: 37497672
doi: 10.1161/STROKEAHA.123.043131
pmc: PMC7614992
mid: EMS178545
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2380-2389Subventions
Organisme : Wellcome Trust
ID : G105713
Pays : United Kingdom
Références
BMJ. 2000 May 13;320(7245):1335
pubmed: 10807635
Head Neck. 2016 Aug;38(8):1242-7
pubmed: 27028850
BMJ Glob Health. 2016 Dec 8;1(4):e000059
pubmed: 28588975
Sci Total Environ. 2021 Jun 25;775:145839
pubmed: 33631580
Lancet. 2018 May 19;391(10134):2071-2078
pubmed: 29627159
Lancet. 2013 Dec 7;382(9908):1898-955
pubmed: 24309475
Lancet. 2020 Oct 31;396(10260):1452-1462
pubmed: 33129396
J Neurosurg Pediatr. 2011 Nov;8(5):509-21
pubmed: 22044378
Front Neurol. 2017 Nov 30;8:651
pubmed: 29250029
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Lancet. 2018 May 19;391(10134):2019-2027
pubmed: 29864018
Lancet. 2015 Apr 27;385 Suppl 2:S56
pubmed: 26313106
Lancet Public Health. 2022 Jan;7(1):e74-e85
pubmed: 34756176
J Benefit Cost Anal. 2019;10(Suppl 1):15-50
pubmed: 32968616
Lancet Glob Health. 2018 Apr;6(4):e436-e446
pubmed: 29496511
BMC Health Serv Res. 2019 Nov 4;19(1):789
pubmed: 31684935
BMC Neurol. 2012 Nov 14;12:137
pubmed: 23150894
Nat Rev Dis Primers. 2019 Oct 10;5(1):70
pubmed: 31601801
Plast Reconstr Surg. 2023 Apr 25;:
pubmed: 37093034
Ann Surg. 2021 Dec 1;274(6):1067-1072
pubmed: 32097168
Eur Stroke J. 2023 Jan;8(1 Suppl):21-27
pubmed: 36793741
Int J Stroke. 2017 Oct;12(8):827-834
pubmed: 28355959
Neurol Sci. 2016 Aug;37(8):1195-202
pubmed: 27129874
J Neurosurg. 2018 May 18;130(4):1149-1156
pubmed: 29775144
Eur J Health Econ. 2019 Feb;20(1):107-134
pubmed: 29909569
J Neurosurg. 2022 Oct 21;:1-9
pubmed: 36272121
Lancet Glob Health. 2015 Apr 27;3 Suppl 2:S21-7
pubmed: 25926317
Lancet Neurol. 2019 May;18(5):439-458
pubmed: 30871944
Lancet Neurol. 2021 Oct;20(10):795-820
pubmed: 34487721
Value Health. 2022 Jan;25(1):3-9
pubmed: 35031096